enGene Holdings Inc. (ENGN) Stock Ticker
ENGN right now
Market factors today
Unlock the full ENGN picture
About enGene Holdings Inc.
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
ENGN stock facts
| Ticker symbol | ENGN |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $131.3M |
| CEO | Ronald H. W. Cooper |
| Employees | 82 |
| Headquarters | Montreal, QC, CA |
| IPO date | 2022-02-01 |
| Website | www.engene.com |
What you can see for ENGN on Tickr
Live ENGN price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the ENGN report.
Rankings
FAQ
What is the ticker symbol for enGene Holdings Inc.?
The ticker symbol for enGene Holdings Inc. is ENGN, listed on the NASDAQ Capital Market.
What is ENGN?
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy…